1. Home
  2. SLNO vs MGNI Comparison

SLNO vs MGNI Comparison

Compare SLNO & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNO
  • MGNI
  • Stock Information
  • Founded
  • SLNO 1999
  • MGNI 2007
  • Country
  • SLNO United States
  • MGNI United States
  • Employees
  • SLNO N/A
  • MGNI N/A
  • Industry
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • MGNI Computer Software: Programming Data Processing
  • Sector
  • SLNO Health Care
  • MGNI Technology
  • Exchange
  • SLNO Nasdaq
  • MGNI Nasdaq
  • Market Cap
  • SLNO 3.8B
  • MGNI 3.1B
  • IPO Year
  • SLNO 2014
  • MGNI N/A
  • Fundamental
  • Price
  • SLNO $68.57
  • MGNI $24.16
  • Analyst Decision
  • SLNO Strong Buy
  • MGNI Strong Buy
  • Analyst Count
  • SLNO 10
  • MGNI 12
  • Target Price
  • SLNO $112.50
  • MGNI $25.75
  • AVG Volume (30 Days)
  • SLNO 1.6M
  • MGNI 2.8M
  • Earning Date
  • SLNO 08-06-2025
  • MGNI 08-06-2025
  • Dividend Yield
  • SLNO N/A
  • MGNI N/A
  • EPS Growth
  • SLNO N/A
  • MGNI N/A
  • EPS
  • SLNO N/A
  • MGNI 0.29
  • Revenue
  • SLNO $32,656,999.00
  • MGNI $685,074,000.00
  • Revenue This Year
  • SLNO N/A
  • MGNI $0.43
  • Revenue Next Year
  • SLNO $209.31
  • MGNI $11.49
  • P/E Ratio
  • SLNO N/A
  • MGNI $84.75
  • Revenue Growth
  • SLNO N/A
  • MGNI 5.52
  • 52 Week Low
  • SLNO $41.50
  • MGNI $8.22
  • 52 Week High
  • SLNO $90.32
  • MGNI $25.27
  • Technical
  • Relative Strength Index (RSI)
  • SLNO 32.58
  • MGNI 58.63
  • Support Level
  • SLNO $66.72
  • MGNI $21.03
  • Resistance Level
  • SLNO $87.17
  • MGNI $24.54
  • Average True Range (ATR)
  • SLNO 3.81
  • MGNI 1.30
  • MACD
  • SLNO -1.52
  • MGNI -0.01
  • Stochastic Oscillator
  • SLNO 21.55
  • MGNI 90.05

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

About MGNI Magnite Inc.

Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.

Share on Social Networks: